2024年欧洲肿瘤内科学会（ESMO）年会将于9月13日至17日在西班牙巴塞罗那隆重举行。作为每年大会的重头戏，LBA（新突破性摘要）研究聚焦Ⅱ期或Ⅲ期随机试验，因其极高的临床应用价值和创新意义，成为引领未来肿瘤治疗的重要风向标。目前，ESMO官网已在线公布了入选LBA的研究题目。为方便读者了解消化肿瘤领域的新进展，消化时讯小编特别整理了12项入选研究信息，其中包括3项来自中国学者的研究，供读者参考。

结直肠癌

口头报告专场1：消化肿瘤-下消化道

地点：Sevilla Auditorium - Hall 2

摘要号：LBA24

标题：Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

局部晚期dMMR结肠癌的新辅助免疫治疗：NICHE-2研究的3年无病生存期

汇报专家：Myriam Chalabi (Amsterdam, Netherlands)

演讲时间：9月15日09:10 - 09:20

口头报告专场1：消化肿瘤-下消化道

地点：Madrid Auditorium - Hall 2

摘要号：LBA25

标题：Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

雷莫西尤单抗联合TAS-102（三氟尿苷/替吡嘧啶）vs. TAS102单药治疗重度预处理转移性结直肠癌的随机Ⅲ期试验：德国AIO (AIO- krk -0316) RAMTAS/IKF643试验

汇报专家：Stefan Kasper-Virchow (Essen, Germany)

演讲时间：9月15日14:45 - 14:55

摘要号：LBA26

标题：SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

SOLARIS（Alliance A021703）：一项随机、多中心、双盲，Ⅲ期试验，采用维生素D联合化疗+贝伐珠单抗治疗未经治疗的转移性结直肠癌患者

汇报专家：Kimmie Ng (Boston, USA)

演讲时间：9月15日14:55 - 15:05

肝癌

主席研讨会I：改变实践的试验

地点：Barcelona Auditorium - Hall 2

摘要号：LBA3

标题：Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study

经动脉化疗栓塞术 (TACE) 联合或不联合仑伐替尼+帕博利珠单抗治疗中晚期肝细胞癌 ：Ⅲ期LEAP-012研究

汇报专家：Josep Llovet (Barcelona, Spain)

演讲时间：9月14日17:30 - 17:42

口头报告专场1：消化肿瘤-上消化道

地点：Sevilla Auditorium - Hall 2

摘要号：LBA38

标题：Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)

Iparomlimab和tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗一线治疗晚期肝细胞癌：一项随机、开放标签、Ⅱ/Ⅲ期研究（DUBHE-H-308）

汇报专家：秦叔逵 教授（中国药科大学附属南京天印山医院）

演讲时间：9月13日16:00 - 16:10

摘要号：LBA39

标题：Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

IMbrave050的新疗效和安全性数据：阿替利珠单抗+贝伐珠单抗辅助治疗vs.主动监测在高危肝细胞癌切除或消融后患者中的Ⅲ期研究

汇报专家：Adam Yopp (Dallas, USA)

演讲时间：9月13日16:10 - 16:20

摘要号：LBA40

标题：Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Ⅲ期ALTN-AK105-III-02研究的主要结果：安罗替尼联合派安普利单抗vs.索拉非尼一线治疗晚期肝细胞癌

汇报专家：周俭 教授（复旦大学附属中山医院）

胃食管癌

口头报告专场2：消化肿瘤-上消化道

地点：Madrid Auditorium - Hall 2

摘要号：LBA58

标题：A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG

围手术期化疗联合或不联合术前放化疗治疗可切除胃癌的随机Ⅲ期试验（AGITG-TOPGEAR）：AGITG、TROG、EORTC和CCTG组间试验的终结果

汇报专家：Trevor Leong (Melbourne, Australia)

演讲时间：9月14日08:30 - 08:40

摘要号：LBA59

标题：Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial

改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗vs. FLOT联合纳武利尤单抗治疗既往未经治疗的晚期或转移性胃或胃食管交界处腺癌患者_IKF-AIO-Moonlight试验的终结果

汇报专家：Sylvie Lorenzen (Munich, Germany)

演讲时间：9月14日08:40 - 08:50

简短口头报告专场：消化肿瘤-上消化道

演讲地点：Bilbao Auditorium - Hall 2

摘要号：LBA60

标题：Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

SHR-1701对比安慰剂联合化疗作为HER2阴性胃/胃食管交界部腺癌一线治疗的Ⅰ期研究

汇报专家：彭智 教授（北京大学肿瘤医院）

演讲时间：9月16日08:30 - 08:35

口头报告专场1：消化肿瘤-上消化道

地点：Sevilla Auditorium - Hall 2

摘要号：LBA62

标题：Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44

术前改良FOLFIRINOX（mFOLFIRINO）联合或不联合放化疗治疗临界可切除性胰腺癌：随机Ⅱ期试验的PANDAS/PRODIGE 44结果

汇报专家：Aurélien Lambert (Nancy, France)

演讲时间：9月13日16:45 - 16:55

简短口头报告专场：消化肿瘤-上消化道

演讲地点：Bilbao Auditorium - Hall 2

摘要号：LBA63

标题：A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy

伊立替康脂质体联合 S-1vs. 伊立替康脂质体联合5-FU二线治疗吉西他滨化疗后转移性胰腺癌患者的随机Ⅰ/Ⅱ期研究

汇报专家：Anne M. Gehrels (Amsterdam, Netherlands)

演讲时间：9月16日08:55 - 09:00